Principal Health News
Medical Library
Cool Tools
Fitness & Nutrition
Women's Health
Men's Health
Pregnancy
Children's Health
Alternative Health
Lifestyle & Wellness
Ills & Conditions
Health After 60
Work & Health
Dental Health
Self-Care Centers
Brought to you by CVS Caremark

About This Site

Registration

FAQ

Contact Us

Privacy

Terms of Use

Site Awards


Baclofen Aids Abstinence in Alcoholics With Cirrhosis

Study finds drug's anti-craving action, safety could play role in liver treatment

FRIDAY, Dec. 7 (HealthDay News) -- The drug baclofen promotes alcohol abstinence in alcoholics with cirrhosis of the liver, says an Italian study in this week's issue of The Lancet.

The study included 84 alcohol-dependent patients with liver cirrhosis who received either oral baclofen (42 patients) or a placebo (42 patients). Total alcohol abstinence and duration of this abstinence were assessed during outpatient visits. Relapse was defined as alcohol intake of more than four standard drinks per day (a standard drink defined as equal to 12 grams of absolute alcohol) or overall consumption of 14 or more standard drinks per week over a period of at least four weeks.

Among those taking baclofen, 71 percent (30 of 42 patients) achieved and maintained alcohol abstinence, compared to 29 percent (12 of 42) of those who took the placebo. The study also found that patients taking baclofen abstained from alcohol for more than twice as long as those taking the placebo -- 62.8 days vs. 30.8 days.

"Our results show that oral administration of baclofen is significantly more effective than placebo at achieving and maintaining alcohol abstinence and at increasing cumulative abstinence duration in alcohol-dependent patients with liver cirrhosis. This reduction in self-reported alcohol use was associated with significant reductions in clinical markers of liver injury, findings that confirm self-reported data and suggest that the reduction in alcohol consumption was sufficient to lessen liver injury," Dr. Giovanni Addolorato, of the Institute of Internal Medicine at the Catholic University of Rome, said in a prepared statement.

"Our results suggest that bacolfen, because of its anti-craving action and safety, could have an important role for treatment of alcohol-dependent patients with advanced liver disease," the researchers concluded.

Alcohol is the most common cause of liver cirrhosis in developed nations, according to background information in the study.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about liver cirrhosis.

SOURCE: The Lancet, news release, Dec. 7, 2007


Copyright © 2007 ScoutNews, LLC. All rights reserved.


Or Find More On:

Back to top of page

  -

Home | Medical Library | Cool Tools | Fitness & Nutrition | Women's Health
Men's Health | Pregnancy | Children's Health | Alternative Health | Lifestyle & Wellness
Ills & Conditions | Health After 60 | Work & Health | Dental Health | Self-Care Centers

About Principal Health News | Editorial Guidelines | Registration | FAQ | Contact Us | Privacy

Copyright© 2002- Principal Financial Services, Inc. Terms of Use.

We subscribe to the HONcode principles of the Health On the Net Foundation URAC Health Web Site Accreditation Seal